Treatment of non‐infectious ophthalmic inflammatory diseases with 1.5% dexamethasone <i>γ</i>‐cyclodextrin nanoparticle eye drops

Imamachi, Katsue; Stefánsson, Einar; Ohira, Akihiro; Tanito, Masaki

doi:10.1111/aos.14119

Cited by 5 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been also reported that the use of an ophthalmic dexamethasone cyclodextrine nanoparticle suspension has optimal results [20]. In this pilot study, the nanosystem is reported to have significant efficacy against uveitic macular edema and vitritis.…”

Section: Anti-inflammatory Nanomedicines In the Clinicmentioning

confidence: 70%

Anti-Inflammatory Nanomedicines: What Does The Future Hold?

Rivero-Sánchez

Calpena

Soriano

et al. 2020

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Anti-inflammatory drugsAnti-inflammatory drugs constitute the backbone of treatment for most diseases. In fact, there is a direct relationship between chronic inflammation and many emerging disorders like cancer, oral diseases, kidney diseases, fibromyalgia, GI chronic diseases or rheumatic diseases [1]. Steroidal anti-inflammatory drugs (SAIDs) and nonsteroidal antiinflammatory drugs (NSAIDs) are key contributors in the treatment of acute inflammatory pain conditions such as headache, postoperative pain and orthopedic fractures as well as in the management of chronic inflammatory pain and inflammatory diseases like rheumatoid arthritis, osteoarthritis and gout and for ocular diseases [2]. The principal therapeutic applications of NSAIDs are related to pain, fever and they can also be used as a prophylaxis treatment after first coronary or cerebrovascular ischemic event, this is one of the most important usages of acetylsalicylic acid (ASA) [3]. Principal therapeutic areas for SAIDs are allergic rhinitis (nasally administered) [4], asthma [5], nasal polyposis and chronic rhinosinusitis [6,7]. Orally administered prednisolone, a SAID, is indicated in bronchial asthma, allergic and inflammatory disorders, rheumatoid arthritis and other collagenopathies, dermatitis and dermatoses such as subacute and chronic eczema, psoriasis and pemphigus. Worldwide anti-inflammatory drug consumptionNowadays, anti-inflammatory medications are one of the most consumed type of drugs worldwide. According to the commercial source of drug utilization IQVIA [8] in 2019, ASA, diclofenac (DIC) and ibuprofen were the three main NSAIDs consumed worldwide. From September 2018 to September 2019, more than 335,000 million standard units or doses were sold. NSAIDs consumption is reported to be a bit higher than SAIDs. The leading market share of NSAIDs and SAIDs market is located in Europe and southeast Asia.In Europe, the market is dominated by NSAIDs, with sales of ASA, DIC and ibuprofen exceeding 12,000 million standard units a year and 16,000 million in the case of ASA. SAIDs also represent a huge market in Europe, among them (in decreasing order) mometasone, beclomethasone, fluticasone and the combination of beclomethasone and formoterol.Concerning the delivery routes of the three most consumed SAIDs worldwide mometasone, fluticasone and prednisolone, the nasal route is predominant (54.7%), followed by the oral (21.6%) and ophthalmic routes (9.9%), but it depends on the drug. These data refer to the year 2019 [8]. Limitations of convectional anti-inflammatory therapiesUnfortunately, current anti-inflammatory therapies are unable to achieve the best conditions of efficacy and safety. It is also important to highlight that anti-inflammatory drugs lead to very expensive and serious adverse events, Nanomedicine (Lond.

show abstract

Section: Anti-inflammatory Nanomedicines In the Clinicmentioning

confidence: 70%

Anti-Inflammatory Nanomedicines: What Does The Future Hold?

Rivero-Sánchez

Calpena

Soriano

et al. 2020

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…34 The OCS-01 eye drops were also investigated for their antiinflammatory effect in 10 human eyes for six patients (five female) complaining of different ocular inflammatory diseases, including anterior scleritis, posterior scleritis, unidentified uveitis, Vogt-Koyanagi-Harada disease with papillitis and cystoid macular oedema. 35 All treated eyes responded to OCS-01 with a rapid resolution of congestion with no patients experiencing impaired visual acuity after the treatment started. 35 Fig.…”

Section: Supramolecular Chemistry In Medicinementioning

confidence: 89%

“…35 All treated eyes responded to OCS-01 with a rapid resolution of congestion with no patients experiencing impaired visual acuity after the treatment started. 35 Fig. 4 shows both eyes of a 45-year-old man with anterior scleritis before ( Fig.…”

Section: Supramolecular Chemistry In Medicinementioning

confidence: 89%

“…After treatment, ocular congestion almost disappeared, and the pain was reduced significantly and did not recur. 35 Poor control of blood glucose levels is implicated with increased morbidity and mortality, especially in hospital intensive care unit (ICU) patients. 36,37 Continuous glucose monitoring over a 24 h period is useful when seeking to acquire control of blood sugar and to avoid hypo-and hyper-glycaemia, especially in diabetic patients.…”

Section: Supramolecular Chemistry In Medicinementioning

confidence: 99%

See 1 more Smart Citation

Advances in applied supramolecular technologies

Haynes²,

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Recent developments have ensued in dramatic improvements in CD-based nanoformulations. For example, DEX-loaded CD NPs were used as eye drops for the treatment of noninfectious ophthalmic inflammatory diseases . There are several similar DEX complexed CD nanoformulations that are established for the treatment of various inflammatory diseases. , …”

Section: Dexamethasone Delivery Systemsmentioning

confidence: 99%

Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems

Madamsetty

Mohammadinejad

Uzielienè

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Dexamethasone (DEX) has been widely used to treat a variety of diseases, including autoimmune diseases, allergies, ocular disorders, cancer, and, more recently, COVID-19. However, DEX usage is often restricted in the clinic due to its poor water solubility. When administered through a systemic route, it can elicit severe side effects, such as hypertension, peptic ulcers, hyperglycemia, and hydro-electrolytic disorders. There is currently much interest in developing efficient DEX-loaded nanoformulations that ameliorate adverse disease effects inhibiting advancements in scientific research. Various nanoparticles have been developed to selectively deliver drugs without destroying healthy cells or organs in recent years. In the present review, we have summarized some of the most attractive applications of DEX-loaded delivery systems, including liposomes, polymers, hydrogels, nanofibers, silica, calcium phosphate, and hydroxyapatite. This review provides our readers with a broad spectrum of nanomedicine approaches to deliver DEX safely.

show abstract

Treatment of non‐infectious ophthalmic inflammatory diseases with 1.5% dexamethasone γ‐cyclodextrin nanoparticle eye drops

Cited by 5 publications

References 4 publications

Anti-Inflammatory Nanomedicines: What Does The Future Hold?

Anti-Inflammatory Nanomedicines: What Does The Future Hold?

Advances in applied supramolecular technologies

Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems

Contact Info

Product

Resources

About